vs
Side-by-side financial comparison of IONIS PHARMACEUTICALS INC (IONS) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.
IONIS PHARMACEUTICALS INC is the larger business by last-quarter revenue ($203.3M vs $140.6M, roughly 1.4× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs -112.8%, a 142.1% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs -10.3%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $-159.0M). Over the past eight quarters, IONIS PHARMACEUTICALS INC's revenue compounded faster (30.4% CAGR vs 20.5%).
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
IONS vs VCYT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $203.3M | $140.6M |
| Net Profit | $-229.4M | $41.1M |
| Gross Margin | 96.1% | 72.5% |
| Operating Margin | -105.5% | 26.4% |
| Net Margin | -112.8% | 29.3% |
| Revenue YoY | -10.3% | 18.5% |
| Net Profit YoY | -119.8% | 704.8% |
| EPS (diluted) | $-1.35 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $203.3M | $140.6M | ||
| Q3 25 | $156.7M | $131.9M | ||
| Q2 25 | $452.0M | $130.2M | ||
| Q1 25 | $131.6M | $114.5M | ||
| Q4 24 | $226.6M | $118.6M | ||
| Q3 24 | $133.8M | $115.9M | ||
| Q2 24 | $225.3M | $114.4M | ||
| Q1 24 | $119.5M | $96.8M |
| Q4 25 | $-229.4M | $41.1M | ||
| Q3 25 | $-128.6M | $19.1M | ||
| Q2 25 | $123.6M | $-980.0K | ||
| Q1 25 | $-146.9M | $7.0M | ||
| Q4 24 | $-104.3M | $5.1M | ||
| Q3 24 | $-140.5M | $15.2M | ||
| Q2 24 | $-66.3M | $5.7M | ||
| Q1 24 | $-142.8M | $-1.9M |
| Q4 25 | 96.1% | 72.5% | ||
| Q3 25 | 98.5% | 69.2% | ||
| Q2 25 | 99.1% | 69.0% | ||
| Q1 25 | 98.9% | 69.5% | ||
| Q4 24 | 98.3% | 66.4% | ||
| Q3 24 | 99.2% | 68.2% | ||
| Q2 24 | 98.2% | 68.1% | ||
| Q1 24 | 98.2% | 64.5% |
| Q4 25 | -105.5% | 26.4% | ||
| Q3 25 | -102.2% | 17.4% | ||
| Q2 25 | 30.9% | -4.0% | ||
| Q1 25 | -111.6% | 2.5% | ||
| Q4 24 | -48.9% | 3.5% | ||
| Q3 24 | -111.1% | 10.4% | ||
| Q2 24 | -29.3% | 4.0% | ||
| Q1 24 | -125.1% | -4.8% |
| Q4 25 | -112.8% | 29.3% | ||
| Q3 25 | -82.1% | 14.5% | ||
| Q2 25 | 27.3% | -0.8% | ||
| Q1 25 | -111.6% | 6.2% | ||
| Q4 24 | -46.1% | 4.3% | ||
| Q3 24 | -105.0% | 13.1% | ||
| Q2 24 | -29.4% | 5.0% | ||
| Q1 24 | -119.5% | -1.9% |
| Q4 25 | $-1.35 | $0.50 | ||
| Q3 25 | $-0.80 | $0.24 | ||
| Q2 25 | $0.70 | $-0.01 | ||
| Q1 25 | $-0.93 | $0.09 | ||
| Q4 24 | $-0.66 | $0.07 | ||
| Q3 24 | $-0.95 | $0.19 | ||
| Q2 24 | $-0.45 | $0.07 | ||
| Q1 24 | $-0.98 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7B | $362.6M |
| Total DebtLower is stronger | $1.8B | — |
| Stockholders' EquityBook value | $489.1M | $1.3B |
| Total Assets | $3.5B | $1.4B |
| Debt / EquityLower = less leverage | 3.71× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.7B | $362.6M | ||
| Q3 25 | $2.2B | $315.6M | ||
| Q2 25 | $2.3B | $219.5M | ||
| Q1 25 | $2.1B | $186.1M | ||
| Q4 24 | $2.3B | $239.1M | ||
| Q3 24 | $2.5B | $274.1M | ||
| Q2 24 | $2.1B | $235.9M | ||
| Q1 24 | $2.2B | $209.2M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $489.1M | $1.3B | ||
| Q3 25 | $618.0M | $1.3B | ||
| Q2 25 | $631.7M | $1.2B | ||
| Q1 25 | $475.7M | $1.2B | ||
| Q4 24 | $588.4M | $1.2B | ||
| Q3 24 | $662.5M | $1.2B | ||
| Q2 24 | $263.7M | $1.1B | ||
| Q1 24 | $296.5M | $1.1B |
| Q4 25 | $3.5B | $1.4B | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $3.0B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $3.1B | $1.3B | ||
| Q2 24 | $2.7B | $1.2B | ||
| Q1 24 | $2.8B | $1.2B |
| Q4 25 | 3.71× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-137.7M | $52.6M |
| Free Cash FlowOCF − Capex | $-159.0M | $48.8M |
| FCF MarginFCF / Revenue | -78.2% | 34.7% |
| Capex IntensityCapex / Revenue | 10.5% | 2.7% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-320.0M | $126.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-137.7M | $52.6M | ||
| Q3 25 | $-131.4M | $44.8M | ||
| Q2 25 | $151.3M | $33.6M | ||
| Q1 25 | $-150.8M | $5.4M | ||
| Q4 24 | $-116.1M | $24.5M | ||
| Q3 24 | $-115.0M | $30.0M | ||
| Q2 24 | $-119.9M | $29.6M | ||
| Q1 24 | $-149.9M | $-9.0M |
| Q4 25 | $-159.0M | $48.8M | ||
| Q3 25 | $-136.7M | $42.0M | ||
| Q2 25 | $139.0M | $32.3M | ||
| Q1 25 | $-163.4M | $3.5M | ||
| Q4 24 | $-141.6M | $20.4M | ||
| Q3 24 | $-124.0M | $27.7M | ||
| Q2 24 | $-126.1M | $26.8M | ||
| Q1 24 | $-154.4M | $-11.1M |
| Q4 25 | -78.2% | 34.7% | ||
| Q3 25 | -87.2% | 31.8% | ||
| Q2 25 | 30.8% | 24.8% | ||
| Q1 25 | -124.1% | 3.1% | ||
| Q4 24 | -62.5% | 17.2% | ||
| Q3 24 | -92.7% | 23.9% | ||
| Q2 24 | -56.0% | 23.4% | ||
| Q1 24 | -129.2% | -11.5% |
| Q4 25 | 10.5% | 2.7% | ||
| Q3 25 | 3.4% | 2.1% | ||
| Q2 25 | 2.7% | 1.0% | ||
| Q1 25 | 9.6% | 1.6% | ||
| Q4 24 | 11.3% | 3.5% | ||
| Q3 24 | 6.8% | 1.9% | ||
| Q2 24 | 2.8% | 2.4% | ||
| Q1 24 | 3.8% | 2.2% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 1.22× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
